Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (285)	1/7/1999 3:46:00 AM
From: Mike McFarland	Read Replies (2) \| Respond to of 656

Sorry Dr. Niman, I am not following you around...just a coincidence. Thread: I want to know more about IL-4 blocker. I heard IMNX had a phase III trial, but I have not seen anything in the paper...would love to be in it--have exercise induced, I should think they would want patients like that, simpler. Anyway, I know it looks like IMNX is the leader here...and I wish I had owned it--happy for you all. However...while I am here I want to ask what you all think of this...from Ariad: I'm not trying to pump aria...I was able to get rid of half my warrants for what I paid for them (1/4) so I have no short term interest in pumping the stock. But what I do want to get is a better understanding of how asthma works so I can confront my HMO, which is not helping me quite as much with my asthma as I would like. from Ariad.com-- ARIAD scientists have made considerable progress in the development of small-molecule compounds that bind to the SH2 domain of Syk. In addition to cloning and producing large quantities of human Syk for binding studies and structural analysis, ARIAD has solved the three-dimensional structure of the Syk SH2 domain using NMR. Using this structural information and other data, ARIAD chemists have designed small-molecule compounds that bind to Syk in in vitro assays. The design and synthesis of small organic molecules that are cell-membrane permeable and bind to Syk are critical milestones in the development of a potent drug to treat allergy/asthma. Using the Company's structure-based combinatorial chemistry technology, ARIAD chemists and biologists are further optimizing lead compounds, and potential candidates will be tested in investigational animal models of airway hyperreactivity and pulmonary functions. any thoughts?